Search results
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Morningstar· 5 days agoMedia Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express ...
Tongue Cancer: Everything You Need to Know
Verywell Health via Yahoo News· 7 days agoTongue cancer, a type of oral cancer, often begins as a painful lump or sore on the side of the tongue that may bleed and resist healing. Here’s what to...
EU regulators approve BeiGene's tislelizumab for lung cancer (NASDAQ:BGNE)
Seeking Alpha· 6 days agoEU regulators have approved BeiGene’s (NASDAQ:BGNE) tislelizumab for the treatment of three types of...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 5 days agoHe also noted Moderna and Merck began testing their combination in squamous cell carcinoma, a form ...
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
Benzinga via Yahoo Finance· 5 days agoIn January, Roche terminated the collaboration and licensing agreement for HOOKIPA’s HB-700 program...
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 3 days agoFusion (FUSN) is expected to provide updates regarding the developmental program of its lead...
EU approves BeiGene's tislelizumab for lung cancer By Investing.com
Investing.com· 6 days agoThe European Commission (EC) has granted approval to tislelizumab for the treatment of non-small ...
The Cancer Screenings Every Young Woman Should Get
The Oprah Magazine via Yahoo News· 7 days agoLung cancer screening If you’re between the ages of 50 and 80 and a current or former smoker, ask your doctor if you should have an annual ...
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 4 days agoThe NDA is supported by results from JUPITER-02, a randomized, double-blind, placebo-controlled, multinational...
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
Morningstar· 5 days agoGlobal licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3Prolonged ...